Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, with tirofiban in healthy volunteers.
Hinder
Markus
M
Paccaly
Anne
A
Frick
Annke
A
Shukla
Umesh
U
Simcox
Kelly
K
Miller
Barry
B
Gebauer
Alexander
A
D000328:Adult; D015415:Biomarkers / Q000097:blood; D001777:Blood Coagulation / Q000187:drug effects; D003497:Cyclic N-Oxides / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004359:Drug Therapy, Combination; D065427:Factor Xa Inhibitors; D006801:Humans; D008297:Male; D010314:Partial Thromboplastin Time; D010974:Platelet Aggregation / Q000187:drug effects; D011725:Pyridines / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000077466:Tirofiban; D014443:Tyrosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics
D015415:Biomarkers; D003497:Cyclic N-Oxides; D065427:Factor Xa Inhibitors; D011725:Pyridines; D014443:Tyrosine; D000077466:Tirofiban; C435830:otamixaban